Best Cardiac and Vascular Disorders Companies in France
The 65 best Cardiac and Vascular Disorders companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Carmat.
Ranked: Best Cardiac and Vascular Disorders companies in France
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Carmat Total artificial heart including right and left ventricles | $193M | 32 mo ago | 177 | Stephane Piat CEO | WordPressMySQLPHP+8 | 5 signals ▼29% Regulatory · Announcements | 121 patents Implantable cardiac prosthesis connection and attachment systems for heart valve integration | — |
| 2 | TISSIUM Developer of vascular sealant for open vascular surgery | $156M | 36 mo ago | 107 | Jeffrey Karp Co-Founder | WordPressPleskMySQL+18 | — | 112 patents Patents concentrated in health & consumer products | 1 award |
| 3 | Abionyx Developer of therapeutics for treating rare diseases and severe inflammatory conditions | $155M | 54 mo ago | 63 | Cyrille Tupin CEO | JoomlaPleskPHP+11 | 5 signals Earnings · Contracts · Capital raise | — | — |
| 4 | CorWave Developer of implantable blood pumps for the treatment of heart failure | $127M | 36 mo ago | 77 | — | WordPressMySQLPHP+11 | — | 88 patents Implantable ventricular assist devices and control systems for cardiac blood pumps | 1 award |
| 5 | Inotrem Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction | $122M | 31 mo ago | 35 | Marc Derive Co-Founder and CSO | WordPressMySQLPHP+23 | — | 52 patents TREM-1 targeted diagnostics and therapeutics for inflammation, sepsis, and cardiovascular risk | — |
| 6 | Limflow Developer a system for venous arterialization of the lower limbs | $97M | 50 mo ago | 46 | — | WordPressMySQLPHP+17 | — | — | — |
| 7 | Withings Developer of an array of connected products | $94M | 70 mo ago | 39 | Eric Carreel Co-Founder | Cart FunctionalityTypeScriptPHP+32 | — | 501 patents Provides wearable health monitoring and point‑of‑care urine analysis technologies. | 5 launchs |
| 8 | Corteria Pharmaceuticals Developer of therapeutics for the treatment of heart failure | $83M | 33 mo ago | 10 | Marie Ozoux Co-Founder | WordPressMySQLPHP+15 | — | 13 patents Therapeutic CRF2 receptor agonist compounds for stress‑related disorder treatment | — |
| 9 | FineHeart Developer of an implantable cardiovascular device for treating heart failures 60Funding top 23%Moat top 26%Growth top 28%Patents top 33% All 9 signals ▾Fundingtop 23% Moattop 26% Growthtop 28% Patentstop 33% Innovationtop 34% Newstop 36% Marketbottom 45% Globalbottom 43% Techbottom 34% Funding: Raised $51.9M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 162 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $52M | 5 mo ago | 50 | — | WordPress Block EditorElementorWordPress+21 | 3 signals Funding | 162 patents Implantable cardiac assist devices and transcutaneous power delivery systems for heart support | — |
| 10 | HighLife Medical Developer of trans-catheter mitral valve replacement system | $51M | 66 mo ago | 70 | — | WordPressMySQLPHP+9 | — | — | 1 award |
| 11 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 79 mo ago | 29 | Gilles Avenard CEO | Webflow EcommerceWebflowApple iCloud Mail+13 | — | 58 patents GPVI‑targeted antibodies for anti‑platelet therapy treating cardiovascular disease | — |
| 12 | CellProthera Developer of cell-based therapies for regenerative medicine, specifically cardiac repair | $31M | 61 mo ago | 30 | Philippe Henon Co-Founder | WordPressMySQLPHP+26 | — | 29 patents Patents concentrated in chemistry & materials | — |
| 13 | Quantum Genomics Small molecule therapeutics for cardiovascular diseases. | $27M | 64 mo ago | 13 | — | — | — | 170 patents Amino‑peptidase A inhibitors for hypertension, heart failure, and renal‑system drugs | — |
| 14 | Stentys Devices for the treatment of acute myocardial infarction and other coronary diseases | $22M | 204 mo ago | 26 | — | — | — | 26 patents Advanced vascular stent delivery devices with frangible bridge structures for controlled deployment | — |
| 15 | CAIRDAC Developer of smart devices for monitoring cardiac rhythm disorders | $19M | 50 mo ago | 23 | Renzo Molin Co-Founder | WordPressMySQLPHP+11 | — | 124 patents Leadless cardiac pacing systems with activity‑adaptive rate control and piezoelectric energy harvesting | — |
| 16 | Arterial Remodeling Technologies Bioresorbable scaffolds to promote natural remodeling of an injured artery after angioplasty | $16M | 189 mo ago | 11 | Machiel Van Der Leest CEO | — | — | 55 patents Patents concentrated in health & consumer products | — |
| 17 | Basecamp Vascular Developer of robotic solution for endovascular access & navigation | $14M | 30 mo ago | 14 | Thierry Col Chief Executive Officer - CEO | — | — | 41 patents Steerable intravascular catheters with controlled curvature and anchoring mechanisms | — |
| 18 | RDS Developer of wearable sensor devices for monitoring cardiac health 35Innovation top 36%Moat top 38%Patents top 45%Funding top 46% All 8 signals ▾Innovationtop 36% Moattop 38% Patentstop 45% Fundingtop 46% Talentbottom 49% Globalbottom 36% Marketbottom 32% Newsbottom 20% Innovation: 28 patents (top 43% of patent-holders) · Deep-tech classification: Tech Hardware Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $14M | 8 mo ago | 22 | Elie Lobel CEO | — | — | 28 patents Patents concentrated in health & consumer products | 1 award |
| 19 | Affluent Medical Developer of minimally invasive prostheses for structural heart disease, vascular therapy, and urology | $12M | 28 mo ago | 52 | Sebastien Ladet CEO | WordPressUnbounceDivi+17 | 4 signals ▲300% M&A | — | — |
| 20 | MITEM Pharma Developer of targeted therapies to treat multiple diseases | $11M | 50 mo ago | — | Eric Thierry Co-Founder & COO | — | — | — | — |
| 21 | Satelia Provider of a device for cardiac health monitoring | $10M | 43 mo ago | 81 | Nicolas PAGES Co-Founder | Apple iCloud MailGoogle WorkspacePHP+14 | — | — | — |
| 22 | Archeon Medical Provider of AI-based device for monitoring cardiology health | $6M | 51 mo ago | 19 | Alban Luca Founder & CEO | WordPressBetterDocsMySQL+26 | — | — | 2 launchs |
| 23 | Lifeaz Developer of connected defibrillators 55Growth top 28%Talent top 28%Tech top 32%Funding top 41% All 10 signals ▾Growthtop 28% Talenttop 28% Techtop 32% Fundingtop 41% Producttop 46% Moattop 47% Marketbottom 47% Patentsbottom 35% Innovationbottom 32% Globalbottom 31% Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $5M | 4 mo ago | 52 | Martial Itty Co-Founder & CTO | Webflow EcommerceCart FunctionalityWebflow+28 | — | 5 patents Portable defibrillation kits integrated with physiological measurement devices for emergency cardiac care | — |
| 24 | Parsys Wireless, digital and portable electrocardiographs and other telemedical devices | $5M | 93 mo ago | 26 | — | WordPressMySQLPHP+22 | — | 5 patents Event‑driven wearable ECG monitoring systems for ambulatory cardiac diagnostics | 1 launch · 1 partnership |
| 25 | Cardiawave Medical device for heart valve disease treatment using histotripsy technology | $4M | 59 mo ago | 36 | — | WordPress Block EditorWordPressMySQL+13 | — | 66 patents Ultrasound‑guided cardiovascular devices for valve treatment, cavitation detection, and stabilization | 1 partnership |
| 26 | Cardio Renal Provider of digital therapeutics solutions for chronic kidney disease (CKD) management | $4M | 50 mo ago | 10 | — | — | — | — | — |
| 27 | Electroducer Developer of devices for coronary interventions and direct wire pacing | $4M | 59 mo ago | — | Lucien Goffart CEO | — | — | 37 patents Intravascular catheters for cardiac diagnostics, valve replacement, and autonomic nerve stimulation. | — |
| 28 | Aterovax Immunoassays for cardiovascular disease | $2M | 150 mo ago | 5 | Gerald Ulrich CEO | — | — | 10 patents Quantitative enzymatic assay kits for measuring phospholipase A1/A2 activity in biological samples | — |
| 29 | Advanced Perfusion Diagnostics Indicators of tissue perfusion impairments | $2M | 127 mo ago | 2 | Fernand Badano CEO | — | — | 24 patents Real-time tissue perfusion and metabolic monitoring via invasive catheters and non‑invasive sensors | — |
| 30 | BodyCap Developer of miniaturized electronic capsule for monitoring core body temperature | $1M | 101 mo ago | 18 | Sebastien Moussay Co-Founder & President | WordPressMySQLPHP+16 | — | 37 patents Patents concentrated in electrical & electronics | — |
| 31 | CMI’nov Provider of minimally invasive surgical devices | $916K | 90 mo ago | 2 | Bernard Pain Co-Founder & CEO | — | — | — | — |
| 32 | ETISENSE Developer of a wearable cardio-respiratory monitoring device | $508K | 71 mo ago | — | Timothe Flenet Co-Founder & CEO | — | — | 14 patents Wearable inductive plethysmography vests for small-animal physiological monitoring | 1 partnership |
Top 12 Cardiac and Vascular Disorders companies in France
#1
Series C · Pessac, Nouvelle Aquitaine · founded 2010 · 50 employees$51.9Mraised▾
Developer of an implantable cardiovascular device for treating heart failures. The device provides long-term circulatory assistance. The I.C.O.M.S. (Implantable Cardiac Output Management System) is synchronized to heart innate contraction and helps to manage heart failure disease.
- Jan 2026Series C$40.8M
- Jan 2026Grant (prize money)$56M
- Oct 2022Grant (prize money)$2.4M
- 2022Grant (prize money)$19.8M
#2
Series B · Paris, Ile de France · founded 2015 · 52 employees$4.7Mraised▾
Developer of connected defibrillators. The Lifeaz Defibrillator provides vocal instructions for usage and to enables the user to place the electrodes on the patient's chest and analyze the cardiac rhythm. The data is collected on the platform which analyses to provide the results. Some of the partners are Allianz, bpifrance, ANOULD, WILCO, Centralelille, and many others.
- Feb 2026Series B$15.5M
- Oct 2021Series A$4.7M
#3
Series A · Strasbourg, Grand Est · founded 2020 · 22 employees$13.7Mraised▾
Developer of wearable sensor devices for monitoring cardiac health. The company is engaged in the development of a lightweight e-health patch MultiSense device that involves the real-time transfer of cardiac and respiratory vital information. The device contains 5 embedded sensors that able to measure vital sign parameters including heart rate, respiratory rate, and oxygen saturation. It uses a proprietary technology that helps to collect chronic information from multiple sensors in an implanted device for evaluation in heart failure patients.
- Sep 2025Series A$16.6M
- Feb 2021Seed$3.6M
#4
Deadpooled · Velizy Villacoublay, Ile de France · founded 2008 · 177 employees$192.7Mraised▾
CARMAT is a medtech company that is developing a biocompatible, auto-regulated total artificial heart including right and left ventricles that us designed to be as close as possible to the human heart. This project has come from collaboration between Professor Alain Carpentier and the Airbus Group in the use of advanced biomaterials and aerospace technologies applied to the artificial heart.
- Oct 2023Post IPO$7.4M
- 2022Grant (prize money)$19.8M
- Apr 2022Post IPO$44.1M
- Sep 2019Post IPO$66.3M
#5
Series B · Paris, Ile de France · founded 2013 · 35 employees$122.5Mraised▾
Inotrem is developing peptide immunotherapies for treating septic shock and acute myocardial infarction. The company is developing drugs that target the TREM-1 pathway. The company's lead candidate, Motrem, is a TREM-1 inhibitor and is a 12 amino-acid peptide, acting as a decoy receptor and interfering with the binding of TREM-1 and its ligand. It is being investigated for septic shock, and for acute myocardial infarction. The drug is in phase I trials.
- Nov 2023Grant (prize money)—
- Dec 2022Grant (prize money)—
- Feb 2020Conventional Debt$15.3M
- Feb 2020Series B$5.5M
#6
Series D · Paris, Ile de France · founded 2013 · 107 employees$156Mraised▾
Developer of vascular sealant for open vascular surgery. The company has developed biomorphic and programmable polymers for natural tissue healing. The flagship product, SETALIUM is a biocompatible, biodegradable, and on-demand activated sealant, designed to help achieve hemostasis during open vascular surgery.
- Jun 2023Conventional Debt$4.5M
- May 2023Series D$54.1M
- Aug 2021Series C$59M
- Oct 2020Conventional Debt$8.2M
#7
Series C · Paris, Ile de France · founded 2011 · 77 employees$126.7Mraised▾
CorWave is developing implantable blood pumps for the treatment of heart failure. The company's products CorWave LVAD, and Nemo, are based on biomimetic technology, the Wave Membrane. CorWave LVAD is a full support implantable pump connected to the left ventricle and intended to treat patients with advanced heart failure. Nemo is a minimally invasive blood pump that is used to provide partial support to heart failure patients who are not suited for LVADs.
- Jun 2023Series C$66.6M
- Jan 2021Series C$43M
- Oct 2020Grant (prize money)$2.9M
- Nov 2016Series B$17.1M
#8
Series A · Paris, Ile de France · founded 2021 · 10 employees$83.3Mraised▾
Developer of therapeutics for the treatment of heart failure. The company is developing transformative therapies for the treatment of worsening and acute decompensated heart failure.
- Sep 2023Series A$69.7M
- Dec 2021Seed$13.6M
#9
Public · Balma, Occitanie · founded 2005 · 63 employees$154.5Mraised▾
Developer of therapeutics for treating rare diseases and severe inflammatory conditions. The pipeline includes CER‑001 a recombinant apoA‑I HDL-mimetic under investigation for cardiovascular, rare genetic LCAT deficiency, severe inflammatory states, and even targeted delivery in oncology, CER-002 a peroxisome proliferator-activated receptor (PPAR) delta specific agonist in development for the treatment of cardiovascular diseases, and CER-209 is a oral P2Y13 receptor agonists for the treatment of atherosclerois and of non-alcoholic steato-hepatitis.
- Dec 2021Post IPO$4.8M
- Mar 2015Series C$4.1M
- Oct 2010Series C$13.9M
- Jul 2010Grant (prize money)$13.8M
#10
Acquired · Paris, Ile de France · founded 2012 · 46 employees$97.5Mraised▾
Developer a system for venous arterialization of the lower limbs. The system employs a minimally invasive, endovascular approach to achieve venous arterialization. Two ultrasound-guided catheters, one venous and one arterial install a crossing nitinol stent, creating an arterio-venous fistula and restoring blood supply to the ischemic foot.
- Apr 2022Series D$40M
- Apr 2018Series C$33.5M
- Oct 2016Series B$24M
- Sep 2014Series A—
#11
Public · Paris, Ile de France · founded 2011 · 52 employees$11.7Mraised▾
Developer of minimally invasive prostheses for structural heart disease, vascular therapy, and urology. It offers Kalios an adjustable mitral annuloplasty ring for mitral valve repair, Epygon a transcatheter mitral valve replacement, and Artus an electronic artificial urinary sphincter for less invasive treatment of urinary incontinence.
- Jan 2024Post IPO$3.8M
- Sep 2022Post IPO$5.8M
- Jun 2020Series B$11.7M
- Nov 2018Conventional Debt$4.5M
#12
Series A · Reims, Grand Est · founded 2016 · 14 employees$14Mraised▾
Developer of robotic solution for endovascular access & navigation. The company offers a GECKO System a unique smart handle single-use steerable mechatronic guidewire intended to facilitate the access and positioning of a catheter to reach the obstructing clot.
- Dec 2023Series A$6.5M
- Jul 2018Grant (prize money)$58.4K
- Feb 2018Grant (prize money)$62.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.